ReElement Technologies stock soars after securing $1.4B government deal
DUBLIN - Investment firm Geode Capital Management, LLC has disclosed a 2.26% stake in Avadel Pharmaceuticals plc, according to a regulatory filing released Monday.
The filing, made under the Irish Takeover Panel rules, reveals that Geode holds 2,197,210 ordinary shares in the pharmaceutical company as of October 31, 2025.
The disclosure also details a recent transaction in which Geode purchased 156 additional Avadel shares at a price of $18.89 per unit.
The filing was made in accordance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
Geode Capital, a global investment management firm, indicated in the filing that it does not have any cash-settled derivatives, stock-settled derivatives, or other arrangements relating to Avadel securities.
The disclosure comes as part of standard regulatory requirements for significant shareholders. The filing stated there are no indemnity arrangements or agreements relating to options or derivatives involving Avadel securities.
Avadel Pharmaceuticals is an Ireland-based biopharmaceutical company focused on developing and commercializing products for central nervous system disorders.
The information was provided in a Form 8.3 filing submitted to the Irish Takeover Panel and released through the Regulatory Information Service of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.